^
    Back
    Association details:
    Biomarker:BRCA1 mutation
    Cancer:Pancreatic Adenocarcinoma
    Drug:Lynparza (olaparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Pancreatic Adenocarcinoma: Principles of systemic therapy…Preferred Regimens...Olaparib (only for germline BRCA1/2 mutations)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Pancreatic Cancer)
    New
    Title:

    Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

    Excerpt:
    AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

    Excerpt:
    ...- Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or suspected deleterious...
    Trial ID:
    POLO